Bluebird Bio Inc
![Bluebird Bio Inc](https://api.admiralmarkets.com/trade_icons/bright-128/BLUE.png)
Fermé
0.52 -7.14
Résumé
Variation du prix de l'action
24h
Min
0.51
Max
0.53
Revenu | -72M |
---|---|
Ventes | 12M |
BPA | -0.66 |
Marge bénéficiaire | -578.849 |
EBITDA | -84M |
Recommandations | Achat |
---|---|
Prévisions sur 12 Mois | +686.79 upside |
Prochains Résultats | 5 nov. 2024 |
---|
Capitalisation Boursière | 5.7M 240M |
---|---|
Ouverture précédente | 7.66 |
Clôture précédente | 0.52 |
Score Technique
By Trading Central
Confiance
Bearish Evidence
Bluebird Bio Inc Graphique
Actualités Associées
Comparaison
Variation de prix
Bluebird Bio Inc prévision
Objectif de Prix
By TipRanks
686.79% hausse
Prévisions sur 12 Mois
Moyen 4.17 USD 686.79%
Haut 6 USD
Bas 3 USD
Basé sur 10 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.
Éléments financiers
Frais Généraux et Administratifs
Dépenses d'exploitation
Résultat avant impôt
Ventes
Coût des ventes
Marge brute des ventes
EBITDA
Bénéfice d'exploitation
$
À Propos Bluebird Bio Inc
bluebird bio, Inc. is a biotechnology company. The Company focusing on researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases and cancer. It develops LentiGlobin for sickle cell disease (SCD) as a one-time treatment for patients with SCD, a hereditary blood disorder resulting from a mutation in the ß-globin gene that causes polymerization of hemoglobin proteins, resulting in abnormal red blood cell function. It builds an integrated product platform with therapeutic in a variety of indications based on its lentiviral gene addition platform, gene editing and cancer immunotherapy capabilities. Its programs in genetic disease include betibeglogene autotemcel; LentiGlobin gene therapy for sickle cell disease (SCD); and elivaldogene autotemcel. Its programs in oncology are focused on developing novel T cell-based immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies.